Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome, Inc. (Nasdaq: IMNM) will participate in a fireside chat hosted by Cantor Fitzgerald's Brian Cheng on December 8, 2021, at 1:00 p.m. ET, aimed at institutional clients. The event will be accessible via webcast, with a replay available on Immunome's website for 30 days following the live presentation.
Immunome utilizes its proprietary human memory B cell platform to develop innovative antibody therapeutics focusing on oncology and infectious diseases, including COVID-19.
Immunome expects its antibody cocktail, IMM-BCP-01, to be effective against the Omicron variant of SARS-CoV-2. The company is performing laboratory testing to confirm this, with results anticipated in January 2022. IMM-BCP-01 targets three distinct epitopes, enhancing its potential resilience against mutations. The cocktail approach aims to improve viral neutralization, as demonstrated in preclinical tests against other variants. Immunome is advancing IMM-BCP-01 towards clinical trials, pending regulatory approval.
Immunome, Inc. (NASDAQ: IMNM) has submitted an Investigational New Drug (IND) application to the U.S. FDA for IMM-BCP-01, a novel three-antibody cocktail targeting SARS-CoV-2. This submission marks a significant milestone for Immunome as they prepare to conduct clinical studies. Preclinical testing shows that IMM-BCP-01 effectively reduces viral load and encompasses broad coverage against various COVID-19 variants. The project is funded by the U.S. Department of Defense, emphasizing its public health importance as COVID-19 continues to pose a threat.
Immunome, Inc. (Nasdaq: IMNM) made progress in its antibody development, notably with IMM-BCP-01, targeting SARS-CoV-2 variants Lambda and Delta Plus. The company plans to submit an IND for IMM-BCP-01 this quarter, alongside anticipated topline data in H1 2022. Financially, for Q3 2021, R&D expenses reached $4.5M, while G&A expenses were $3.2M, leading to a net loss of $7.7M. As of September 30, 2021, cash reserves stood at $56.3M, indicating sufficient resources for ongoing projects.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company specializing in first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Stifel Healthcare Conference on November 15, 2021, at 8:00 a.m. ET. Interested listeners can access the live audio webcast via the Investor Relations section of Immunome's website, with a replay available for 30 days post-event. Immunome focuses on developing therapies for oncology and infectious diseases, including COVID-19, leveraging its proprietary human memory B cell platform.
Immunome (Nasdaq: IMNM) has submitted a preprint manuscript detailing the preclinical efficacy of its SARS-CoV-2 antibody cocktail, IMM-BCP-01. This cocktail includes three monoclonal antibodies targeting regions of the spike protein, showing significant viral load reduction in infected hamsters. In tests, IMM-BCP-01 demonstrated a potent reduction of live viral titers by approximately 3.2 - 4 logs. This research indicates broad protective capabilities against multiple variants, supporting the potential for non-intravenous delivery in humans.
Immunome, Inc. (Nasdaq: IMNM) presented findings on its anti-interleukin-38 monoclonal antibody program at the 2021 AACR-NCI-EORTC International Conference. The presentation revealed that the antibody effectively binds to IL-38, preventing its interaction with receptors and enhancing myeloid cell activity in vitro. In murine tumor models, the antibody significantly inhibited tumor growth. This data suggests that blocking IL-38 could potentially reverse immune suppression in tumors, providing a promising avenue for cancer treatment.
Immunome, Inc. (NASDAQ: IMNM) announced an oral poster presentation of its anti IL-38 antibody program at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 7-10, 2021. The presentation, titled “IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody,” will cover the antibody's effectiveness in inducing robust anti-tumor responses in vivo. This marks a significant milestone for Immunome as it advances its therapeutic programs targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company focused on antibody therapeutics, announced that President and CEO Purnanand Sarma, Ph.D., will present at the Cantor Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Interested parties can access the live audio webcast through the company's Investor Relations page. Immunome leverages its human memory B cell platform to develop first-in-class therapeutics targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced that its President and CEO, Purnanand Sarma, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 9:55 a.m. ET. The live audio webcast can be accessed from the Investor Relations section of the company's website and will be available for replay for 30 days following the event. Immunome is focused on developing first-in-class antibody therapeutics, targeting oncology and infectious diseases, including COVID-19.